<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712049</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0-2007</org_study_id>
    <nct_id>NCT00712049</nct_id>
  </id_info>
  <brief_title>Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)</brief_title>
  <acronym>NASCIT</acronym>
  <official_title>Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidaemia is characterized by low plasma levels of high-density lipoprotein cholesterol&#xD;
      (HDL-c), elevated triglycerides and an increase in low density lipoprotein (LDL-c) particles,&#xD;
      and has been unequivocally established as a most important cardiovascular risk factor. While&#xD;
      statins are effective in reducing plasma levels of LDL-c, these drugs have only modest&#xD;
      effects on raising HDL-c (typically by less than 10%), even with aggressive statin therapy.&#xD;
      However, increasing evidence suggests that low HDL-c might be at least as relevant as high&#xD;
      LDL-c in promoting the development and progression of atherosclerosis. The beneficial effect&#xD;
      of raising HDL-c on clinical outcome has already been demonstrated by several studies.&#xD;
&#xD;
      Nicotinic acid is the most potent agent available for raising plasma levels of HDL-c by up to&#xD;
      29% at clinically recommended doses, and substantially lowers triglycerides and LDL-c.&#xD;
      Furthermore, nicotinic acid is also the most potent lipid lowering agent available that&#xD;
      reduces Lp(a), an independent marker of cardiovascular risk. In a recent study patients with&#xD;
      coronary artery disease had a 21% increase in HDL-c and a 13% decrease in triglycerides, and&#xD;
      these beneficial effects on lipid status may have contributed to a stabilization or&#xD;
      regression of carotid intima-media-thickness (IMT).The impact in patients with advanced&#xD;
      atherosclerosis like peripheral artery disease (PAD) in unknown.&#xD;
&#xD;
      The investigators hypothesized that nicotinic acid in addition to statin therapy may inhibit&#xD;
      progression of peripheral arterial atherosclerosis. Therefore, the aim of the present&#xD;
      randomized controlled trial is to investigate the effects of nicotinic acid (daily dose&#xD;
      starting with 500 mg, up to 2000mg) in addition to simvastatin (40 mg daily) versus&#xD;
      simvastatin (40mg daily) monotherapy in patients with low serum HDL-C levels and PAD with&#xD;
      respect to changes of carotid and femoral IMT, changes of patients´ lipid status and&#xD;
      occurrence of major adverse cardiovascular events (MACE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of carotid and femoral IMT from baseline to 6 and 12 months follow up and occurrence of major adverse cardiovascular events (MACE)</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of grey scale median (GSM) score from baseline to follow-up, and changes of serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides and lipoprotein (a).</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotinic acid + Simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>simvastatin 40 mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic Acid</intervention_name>
    <description>daily dose starting with 500 mg, up to 2000mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PAD defined as an ABI ≤0.9 or &gt;1.3 in patients with low serum HDL cholesterol levels&#xD;
             (&lt;45mg/dL in men, &lt;55 mg/dL in women)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Elevated liver enzymes (above 2 times the normal level)&#xD;
&#xD;
          -  Skeletal muscle myopathy or elevated serum CK levels&#xD;
&#xD;
          -  Allergy or hypersensibility to either statins or nicotinic acid&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renate Koppensteiner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Angiology, Department of Internal Medicine II, Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renate Koppensteiner, Prof. Dr.</last_name>
      <phone>00431404004671</phone>
      <email>renate.koppensteiner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Martin Schillinger, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jasmin Amighi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Schila Sabeti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Renate Koppensteiner</name_title>
    <organization>Medical University Vienna</organization>
  </responsible_party>
  <keyword>intima-media-thickness</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>progression of atherosclerosis</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>major cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

